Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 7686 results

  1. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Robot-assisted surgery for orthopaedic procedures: early value assessment

    In development [GID-HTE10043] Expected publication date: 31 March 2025

    Health technology evaluations
    In development

  3. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]: evaluation consultation

    We are listening to your views on this Highly specialised technology. Comments close 21 November 2024.

    Highly specialised technologies guidance
    In consultation

  4. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  6. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458

    Awaiting development [GID-TA11477] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development [GID-TA11087] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: 09 January 2025

    Technology appraisal guidance
    Awaiting development

  10. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Compression products for treating venous leg ulcers: late stage assessment

    In development [GID-HTE10048] Expected publication date: 27 August 2025

    Health technology evaluations
    In development

  12. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development [GID-TA10700] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  14. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 16 July 2025

    NICE guideline
    In development

  15. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development